Trials / Completed
CompletedNCT03733587
GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors
A Phase 1b Study of GX-I7 in Combination With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Genexine, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1b study to explore the safety and efficacy of GX-I7 in combination with CPA in patients with metastatic or recurrent solid tumors.
Detailed description
This is a Phase 1b study to explore the safety and efficacy of GX-I7 in combination with CPA in patients with metastatic or recurrent solid tumors. This is 4 dose levels and increase dose level after confirm DLT of the previous dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GX-I7 | GX-I7 25mg/ml/vial |
| DRUG | Cyclophosphamide | Cyclophosphamide 500mg/vial |
Timeline
- Start date
- 2018-10-17
- Primary completion
- 2020-04-02
- Completion
- 2020-05-13
- First posted
- 2018-11-07
- Last updated
- 2020-05-14
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03733587. Inclusion in this directory is not an endorsement.